The role of the renin-angiotensin system in acute lung injury

van Asperen, R.M.

Citation for published version (APA):
chapter 3
Ventilator-induced inflammatory response in LPS-exposed rat lung is mediated by angiotensin-converting enzyme

Roelie M. Wösten-van Asperen
René Lutter
Patricia A.C. Specht
Job B. van Woensel
Chris M. van der Loos
Sandrine Florquin
Burkhard Lachmann
Albert P. Bos

Abstract

Angiotensin-converting enzyme (ACE) mediates the ventilator-induced inflammatory response in healthy lungs via angiotensin II (Ang II). A rat model was used to examine the role of ACE and Ang II in the inflammatory response during mechanical ventilation of preinjured (ie lipopolysaccharide [LPS]-exposed) lungs. When indicated, rats were pretreated with the ACE inhibitor captopril and/or intratracheal administration of LPS. The animals were ventilated for 4 hours with moderate pressure amplitudes. Nonventilated animals served as controls. ACE activity and levels of Ang II and inflammatory mediators (interleukin-6, Cytokine-induced Neutrophil Chemoattractant (CINC)-3, interleukin-1β and interleukin-10) were determined in bronchoalveolar lavage fluid (BALF). The localization of ACE and Ang II type 1 receptor in lung tissue was determined by immunohistochemistry. The role of the Ang II pathway was assessed using its receptor antagonist losartan.

Mechanical ventilation of LPS-exposed animals increased ACE activity and levels of inflammatory mediators in BALF compared with ventilated nonexposed and LPS-exposed nonventilated animals. Blocking ACE by captopril attenuated the lung inflammatory response. Furthermore, increased ACE activity in BALF was accompanied by increased levels of Ang II and enhanced expression of its receptor on alveolar cells. Blocking the Ang II receptor attenuated the inflammatory mediator response to a larger extent than by blocking ACE.

In conclusion, during mechanical ventilation ACE, via Ang II, mediates the inflammatory response of both healthy and preinjured lungs.
Introduction

Acute respiratory distress syndrome (ARDS) is the most severe form of acute lung injury (ALI) and is characterized by severe hypoxemia, diffuse alveolar injury, pulmonary edema, and an excessive inflammatory response (Ware and Matthay, 2000). Although mechanical ventilation (MV) can be life-saving for patients with ALI/ARDS, it may induce lung injury, known as ventilator-induced lung injury (VILI), with characteristics similar to that caused by ARDS (Dreyfuss and Saumon, 1998; Tremblay and Slutsky, 1998; Frank et al., 2006). Mechanical ventilation of animals with lungs preinjured by intratracheal instillation of bacterial components such as lipopolysaccharide (LPS) resulted in markedly higher inflammatory responses compared with ventilated animals without preinjured lungs (Altermeier et al., 2005; Whitehead et al., 2004; Dhanireddy et al., 2006; Moriyama et al., 2004).

Clinical and experimental studies found an association between the renin-angiotensin system (RAS) and ALI/ARDS (Marshall et al., 2002; Imai et al., 2005). RAS also plays a key role in the injurious effects of mechanical ventilation (Wösten-van Asperen et al., 2008; Jerng et al., 2007). In healthy rats, inhibition of the RAS component angiotensin-converting enzyme (ACE) attenuated inflammation and lung injury during mechanical ventilation with high tidal volumes (Wösten-van Asperen et al., 2008). The effect of ACE on the inflammatory response may be explained by the fact that ACE generates the key factor of the RAS, angiotensin II (Ang II). Ang II stimulates expression of proinflammatory mediators such as interleukin-8/Cytokine-induced Neutrophil Chemoattractant (CINC)-3 and interleukin-6 via the type 1 and type 2 Ang II receptors (Esteban et al., 2004; Ruiz-Ortega et al., 2002; Suzuki et al., 2003). Indeed, a similar attenuation of the inflammatory response was obtained during injurious mechanical ventilation by blocking the Ang II receptor or by treating with an ACE inhibitor (Wösten-van Asperen et al., 2008; Jerng et al., 2007).

The present study investigates whether ACE mediates the exaggerated inflammatory response to mechanical ventilation of LPS-exposed lungs as reflected by inflammatory mediator levels in bronchoalveolar lavage fluid (BALF), and whether ACE inhibition dampens this response. The role of Ang II in this process was also assessed by using its specific receptor antagonist.
Materials and Methods

Animal Preparation

The study was approved by the ethical committee for animal experiments of the Erasmus Medical Center. The experiments were performed in a total of 81 male adult Sprague-Dawley rats, weighing 270 ± 25 g (Harlan CPB, Zeist, The Netherlands). A tracheostomy was performed under inhalation anesthesia, and the carotid artery was catheterized. Anesthesia was maintained by hourly intraperitoneal injections of pentobarbital sodium (60 mg·kg⁻¹; Nembutal®; Algin BV, Maassluis, The Netherlands). Muscle relaxation was obtained with 2 mg·kg⁻¹ pancuronium bromide (Pavulon®; Organon, Boxtel, The Netherlands) intramuscular hourly.

Experimental Protocol

From a group of 18 animals, 9 were pretreated with 500 mg l⁻¹ captopril (ACE inhibitor) in their drinking water for 5 days, and nine were not. After preparation, animals were connected to a Servo ventilator 300 (Siemens-Elema, Solar, Sweden) and ventilated for 4 hours in a pressure controlled time-cycled mode with moderate pressure amplitudes: peak inspiratory pressure (PIP) 26 cmH₂O and positive end-expiratory pressure (PEEP) 5 cmH₂O (tidal volume approximately 18 ml/kg). Respiratory rate was set at a frequency of 30 per min (inspiratory/expiratory ratio of 1:2) and, to maintain normocapnia, adjusted when necessary. Because oxygen requirements are usually increased in patients with ALI/ARDS, we chose to study the effects of ACE inhibition on inflammation in rats ventilated with a fraction of inspired oxygen (FiO₂) of 1.0. Blood gas analyses and blood pressure were recorded just before and hourly after randomization. Nonventilated animals (n = 9) served as controls.

To determine whether the effects of ACE inhibition on VILI were changed by the administration of an inflammatory stimulus, an additional group of 18 rats received 16 mg·kg⁻¹ LPS (Salmonella Abortus Equi S form, Metalon BmbH, Wusterhausen, Germany) intratracheally 24 hours before the ventilation period. Of these LPS-exposed rats, nine were pretreated with captopril and nine were not (see above) and all were subsequently ventilated for 4 hours with the same moderate pressure amplitudes as above.

Animals were sacrificed with an overdose of intra-arterial administered pentobarbital sodium. Bronchial lavage was performed (n = 6 per group) five times with normal saline (30 ml/kg⁻¹). The retrieved BALF was centrifuged (300 x g at 4°C for 10 minutes), and the supernatant was stored in aliquots at -80°C. After the lavage, pressure-volume (P/V) characteristics of the lungs in opened chest were determined (Lachmann et al., 1980). Lavage was not performed in animals used for histology and immunohistochemistry. From these animals (n = 3 per group), lungs were dissected and recruited by a positive
airway pressure of 10 cmH$_2$O, after which they were fixed in 4% buffered formalin and embedded in paraffin.

Role of Ang II
To further delineate whether ACE exerted its effects via Ang II, an additional group of nine LPS-exposed rats were pretreated for 5 days with the Ang II type 1 receptor antagonist losartan (MSD, Haarlem, The Netherlands; 200 mg l$^{-1}$ added to the drinking water). Hereafter, the animals were ventilated with the same moderate pressure amplitudes as above. After 4 hours of mechanical ventilation, bronchial lavage (n = 6 per group) was performed. Alternatively, lungs were excised and fixed for histological evaluation (n = 3 per group) as described above.

Assays

Measurement of RAS components and inflammatory mediators
ACE activity was measured in BALF by monitoring the degradation of the fluorogenic peptide substrate Mca-R-P-P-F-S-A-F-K(Dnp)-OH (R&D Systems, Uithoorn, The Netherlands), as described previously (Wösten-van Asperen et al., 2008). Ang II was quantified in BALF by using a radioimmunoassay (BioSource, Nivelles, Belgium), according to the manufacturer’s instructions. Interleukin-6 was measured using a rat-specific ELISA kit (BioSource). BALF levels of CINC-3, interleukin-1β and interleukin-10 were measured using rat Fluorokine MAB assays (R&D Systems) and read with a BioRad Bioplex 100. Finally, total protein was measured by the Bradford method (BioRad assay, Munich, Germany) by using bovine serum albumin as a reference.

Histology and immunohistochemistry
Lung sections were scored for lung injury, including the following: (1) alveolar and capillary edema, (2) intravascular and peri-bronchial influx of inflammatory cells, (3) thickness of the alveolar wall, and (4) hemorrhage. The items were semi-quantitatively scored as none, minimal, light, moderate or severe (score 0, 1, 2, 3, or 4, respectively) by a pathologist blinded to the experimental group. The lung injury score was obtained by averaging the score from the animals within each group.

Immunohistochemical staining for ACE and angiotensin II type 1 receptor (AT1) in lung tissue was performed by using a monoclonal mouse anti-ACE antibody (clone 2E2, dilution 1:100) and a polyclonal rabbit anti-AT1 antibody (dilution 1:250; both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), respectively. For optimal immunostaining, tissue pretreatments were needed with heat-induced antigen retrieval (20 minutes, 98 °C) using either Tris/EDTA, pH 9.0 (ACE) or sodium citrate 10 mM, pH 6.0 (AT1). For staining of AT1, a tyramide signal amplification procedure (Catalyzed System Amplification (CSA)
II kit, Dako, Glostrup, Denmark) was performed according to the vendor’s instructions. ACE and AT1 staining was visualized with 3,3’-diaminobenzidine (Dako) as chromogen. Negative controls, replacing the primary antibodies with irrelevant immunoglobulins (same isotype and concentration), were included.

To identify the ACE- and AT1-positive cells in the alveolar septa, double staining was performed combining anti-ACE and anti-AT1 antibodies (see above) with mouse anti-rat macrophage marker ED-1 (Serotec, Oxford, UK) or mouse-anti broad spectrum cytokeratin (ie epithelial) marker AE1/AE3 (NeoMarker, Fremont, CA, USA). For double staining a sequential double alkaline phosphatase method was used (van der Loos and Teeling, 2008). Briefly, first ACE or AT1 was stained in blue (alkaline phosphatase, Vector Blue) and after an intervening heat step (10 minutes, 98°C), the anti-ED-1 or anti-AE1/AE3 antibody was stained in red (alkaline phosphatase, Dako Liquid Permanent Red).

Quantification for ACE and AT1-positive cells was calculated as the ratio of suitable binary threshold image and the total field area. After immunostaining of AT1 using the brown dianobenzidine reaction product, tissue sections were counterstained with eosin for marking the total tissue surface. The Nuance Spectral Imaging System 2.4.0 (CRI, Woburn, MA, USA) enables the user to “unmix” both signals based on their spectral characteristics (Levenson and Mansfield, 2006). For each sample, the mean staining area was obtained by analysis of 10 different fields (x20), excluding vessels. The staining score is expressed as percent positive area in the total area under examination.

Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 5.01 (GraphPad Software, San Diego, USA). Group comparisons were evaluated by one-way analysis of variance, followed by Student-Newman-Keuls for pair-wise multiple comparisons, or the Kruskall-Wallis test, where appropriate. Physiological parameters were evaluated by repeated measures analysis of variance. A p-value < 0.05 was considered significant.

Results
Physiological responses over time
When indicated, rats received LPS intratracheally and/or a pretreatment with captopril (see Materials and Methods). Hereafter, the animals were ventilated with moderate pressure amplitudes (PIP 26/PEEP 5 cmH₂O). Nonventilated animals served as controls.

Blood pressure of the captopril-pretreated and the LPS-exposed animals showed a significant reduction compared to nonpretreated/non-LPS exposed animals (Table 1). In the nonpretreated animals, mechanical ventilation resulted in a decrease in PaCO₂ levels during the first hour (p < 0.05). pH values in LPS-exposed animals without captopril
ACE activity and Ang II
Whereas ventilation of animals without LPS-exposure increased BALF ACE activity compared with controls (p<0.05; Figure 2A), intratracheal instillation of LPS in nonventilated animals did not result in increased BALF ACE activity. Interestingly, in ventilated rats exposed to LPS, there was an eightfold increase of BALF ACE activity compared with non-LPS exposed ventilated animals (p<0.05; Figure 2A). In the ventilation group, pretreatment with captopril of animals exposed to LPS normalized ACE activity to the levels observed in ventilated animals without LPS exposure.

BALF Ang II levels paralleled BALF ACE activity. Ang II levels were twofold higher in the non-LPS exposed ventilated animals compared with the nonventilated animals (p < 0.05; Figure 2B). Intratracheal instillation of LPS did not influence BALF Ang II levels in the nonventilated animals. However, compared with the non-LPS exposed animals, an additional twofold increase was observed when the LPS-exposed animals were ventilated (p<0.05). This increase could be diminished by pretreatment with captopril (p<0.05).
Chapter 3

Table 1 Physiological parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre</th>
<th>1 hour</th>
<th>2 hours</th>
<th>3 hours</th>
<th>4 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-LPS without captopril</td>
<td>129 ± 27</td>
<td>142 ± 13</td>
<td>135 ± 20</td>
<td>125 ± 12</td>
<td>120 ± 25</td>
</tr>
<tr>
<td>Non-LPS with captopril</td>
<td>111 ± 17</td>
<td>118 ± 16*</td>
<td>107 ± 26*</td>
<td>95 ± 24*</td>
<td>96 ± 14</td>
</tr>
<tr>
<td>LPS without captopril</td>
<td>119 ± 17</td>
<td>114 ± 22*</td>
<td>103 ± 26*</td>
<td>101 ± 18*</td>
<td>107 ± 14</td>
</tr>
<tr>
<td>LPS with captopril</td>
<td>130 ± 20</td>
<td>114 ± 22*</td>
<td>111 ± 21*</td>
<td>106 ± 23*</td>
<td>99 ± 24</td>
</tr>
<tr>
<td>PaCO₂ (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-LPS without captopril</td>
<td>29.28 ± 5.85</td>
<td>24.64 ± 4.61**</td>
<td>26.60 ± 4.84#</td>
<td>25.91 ± 5.62</td>
<td>25.30 ± 4.20</td>
</tr>
<tr>
<td>Non-LPS with captopril</td>
<td>28.61 ± 2.83</td>
<td>28.08 ± 4.30</td>
<td>28.34 ± 3.11</td>
<td>27.29 ± 3.02</td>
<td>26.13 ± 2.73</td>
</tr>
<tr>
<td>LPS without captopril</td>
<td>30.27 ± 3.20</td>
<td>23.31 ± 1.99**</td>
<td>27.09 ± 4.96#</td>
<td>28.92 ± 4.58</td>
<td>28.84 ± 3.67</td>
</tr>
<tr>
<td>LPS with captopril</td>
<td>27.02 ± 4.28</td>
<td>25.31 ± 4.26</td>
<td>27.21 ± 2.67</td>
<td>26.37 ± 3.16</td>
<td>25.59 ± 2.81</td>
</tr>
<tr>
<td>pH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-LPS without captopril</td>
<td>7.48 ± 0.07</td>
<td>7.50 ± 0.05</td>
<td>7.49 ± 0.05</td>
<td>7.47 ± 0.06</td>
<td>7.45 ± 0.07</td>
</tr>
<tr>
<td>Non-LPS with captopril</td>
<td>7.47 ± 0.06</td>
<td>7.46 ± 0.04</td>
<td>7.46 ± 0.04</td>
<td>7.49 ± 0.04</td>
<td>7.47 ± 0.04</td>
</tr>
<tr>
<td>LPS without captopril</td>
<td>7.52 ± 0.05</td>
<td>7.59 ± 0.04**</td>
<td>7.54 ± 0.04#</td>
<td>7.53 ± 0.07</td>
<td>7.52 ± 0.05</td>
</tr>
<tr>
<td>LPS with captopril</td>
<td>7.56 ± 0.06</td>
<td>7.51 ± 0.07</td>
<td>7.47 ± 0.03</td>
<td>7.48 ± 0.07</td>
<td>7.45 ± 0.08</td>
</tr>
<tr>
<td>PaO₂ (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-LPS without captopril</td>
<td>≥187.71 ± 62.02</td>
<td>532.31 ± 54.25</td>
<td>538.78 ± 36.71</td>
<td>536.79 ± 40.41</td>
<td>524.19 ± 42.21</td>
</tr>
<tr>
<td>Non-LPS with captopril</td>
<td>514.62 ± 53.95</td>
<td>525.21 ± 59.47</td>
<td>510.10 ± 34.52</td>
<td>529.79 ± 23.83</td>
<td>519.82 ± 40.47</td>
</tr>
<tr>
<td>LPS without captopril</td>
<td>540.43 ± 59.87</td>
<td>565.11 ± 82.84</td>
<td>531.50 ± 150.90</td>
<td>497.43 ± 165.48</td>
<td>486.60 ± 170.01</td>
</tr>
<tr>
<td>LPS with captopril</td>
<td>580.86 ± 62.17</td>
<td>553.98 ± 67.85</td>
<td>528.86 ± 55.18</td>
<td>533.38 ± 103.17</td>
<td>511.58 ± 108.89</td>
</tr>
</tbody>
</table>

Physiological parameters during mechanical ventilation of non-LPS and LPS-exposed animals ventilated at positive inspiratory pressure (PIP) 26 cmH2O/positive end-expiratory pressure (PEEP) 5 cmH2O, with or without pretreatment with captopril. Data are presented as mean ± SD. *p < 0.05, compared with non-LPS exposed animals without pretreatment with captopril. **p < 0.05, compared with time point "pre", #p < 0.05, compared with time point "1 hour".

Protein content and inflammatory mediators

Mechanical ventilation and/or intratracheal administration of LPS significantly increased BALF protein content (mean ± SD: 162 ± 63 µg/ml [MV], 183 ± 71 µg/ml [LPS] and 258 ± 111 µg/ml [LPS + MV] vs. 49 ± 25 µg/ml [control]). Pretreatment with captopril had no significant effect on BALF protein content in any of the experimental groups. The levels of the inflammatory mediators interleukin-6, CINC-3, and interleukin-1β paralleled each other (Figure 3A-C). Mechanical ventilation (interleukin-6 and CINC-3) and/or exposure to LPS (interleukin-6 and interleukin-1β) enhanced levels of the inflammatory mediators compared to non-LPS exposed, nonventilated animals (p < 0.05). Mechanical ventilation of LPS-exposed animals resulted in a further increase of all three mediator levels (p < 0.05 for interleukin-6 and interleukin-1β, CINC-3, not significant). Pretreatment with captopril caused a significant decrease of the mediator levels in both nonexposed (for interleukin-6) and LPS-exposed ventilated animals (interleukin-6 and interleukin-1β). Captopril pretreatment attenuated CINC-3 levels in the non-LPS exposed and LPS-exposed
animals in a trend-wise manner, albeit the difference was not significant. Whereas BALF interleukin-10 levels were not detectable in either of the other groups, ventilation of LPS-exposed animals resulted in a marked increase of these levels ($p < 0.05$; Figure 3D). In this latter group, captopril pretreatment significantly reduced interleukin-10 levels.

**Contribution of Ang II**

To further elucidate the contribution of Ang II to the exaggerated inflammatory mediator responses in LPS-exposed ventilated animals, its receptor antagonist losartan was used (Figure 4). If the effects of ACE on inflammatory mediator production were mediated by Ang II, blocking the Ang II receptor would yield the same effect as blocking ACE with captopril. Indeed, blocking Ang II receptors with losartan resulted in an even stronger effect of reduced BALF protein content (Figure 4A) and BALF inflammatory mediator levels (interleukin-6, CINC-3, interleukin-1β and interleukin-10; Figure 4B-E) in ventilated, LPS-exposed animals as observed after captopril pretreatment.
Figure 3. Whisker plots of levels of interleukin (IL)-6 (A), CINC-3 (B), IL-1β (C) and IL-10 (D) in bronchoalveolar lavage fluid of non-LPS, nonventilated (controls), only mechanically ventilated (MV), only LPS-exposed (LPS) and LPS-exposed mechanically ventilated (LPS + MV) animals with or without pretreatment with captopril. Animals were ventilated at positive inspiratory pressure (PIP) 26 cmH₂O/positive end-expiratory pressure (PEEP) 5 cmH₂O. Data are expressed as median ± range. N = 6 per group. * p<0.05, compared with non-LPS exposed nonventilated animals (control); ** p<0.05, compared with ventilated non-LPS exposed animals (MV only) without captopril pretreatment; # p<0.05, compared with nonventilated LPS-exposed animals (LPS only) and ventilated non-LPS exposed animals (MV only); † p<0.05, compared with non-LPS exposed, nonventilated (control) and ventilated (MV only) animals; ‡ p<0.05, compared with ventilated LPS-exposed animals (LPS + MV) without captopril pre-treatment.
Lung injury score and immunohistochemistry

Histological evaluation of lung tissue from non-LPS exposed ventilated animals showed slightly increased injury when compared with nonventilated animals, albeit the difference was not significant (Table 2, Figure 5, A-H). In nonventilated animals, LPS exposure resulted in significantly higher lung injury scores compared with healthy nonventilated and even healthy ventilated animals (Table 2, Figure 5). Ventilation of the LPS-exposed animals further increased lung injury scores, albeit the difference was not significant. Pretreatment with captopril had no significant effect on lung injury scores.

Immunohistochemical staining of ACE in lung tissue revealed positive staining of endothelial cells (Figure 6, A-F). However, also cells in the alveolar walls were ACE-positive. Double staining of the lung tissue showed that these ACE-positive cells are alveolar macrophages and alveolar epithelial cells (Figure 7, A-D). Neither mechanical ventilation nor LPS caused
any changes in the localization and intensity of staining. Also, pretreatment with captopril had no influence on the number and nature of ACE-positive cells.

In the non-LPS exposed animals, AT1-positive cells were detected only with a high concentration AT1 antibody (1:50; data not shown). This result was irrespective of ventilation or captopril treatment. In contrast, after LPS exposure, AT1-positive cells were already found by using a 1:250 dilution of the antibody (Figure 8, A-D). Ventilation of LPS-exposed animals increased the surface area of AT1-staining in the tissue from 5% in nonventilated animals to 9.5% in the ventilated animals, albeit the difference was

### Table 2 Lung injury scores

<table>
<thead>
<tr>
<th>Group</th>
<th>Congestion</th>
<th>Leukocytes</th>
<th>Thickness</th>
<th>Hemorrhage</th>
<th>Total injury score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Perivascular</td>
<td>Alveolar</td>
<td>Peri-bronchial</td>
<td>Alveolar wall</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.5 ± 0.5</td>
<td>0.3 ± 0.6</td>
<td>0.0 ± 0.0</td>
<td>0.7 ± 0.6</td>
<td>0.7 ± 0.6</td>
</tr>
<tr>
<td>Non-LPS Cap-</td>
<td>0.7 ± 0.6</td>
<td>0.0 ± 0.0</td>
<td>0.0 ± 0.0</td>
<td>0.3 ± 0.6</td>
<td>1.0 ± 0.0</td>
</tr>
<tr>
<td>LPS-Cap-</td>
<td>1.8 ± 0.3</td>
<td>2.3 ± 0.6</td>
<td>2.7 ± 0.6</td>
<td>2.2 ± 0.3</td>
<td>2.5 ± 0.5</td>
</tr>
<tr>
<td>LPS-Cap+</td>
<td>2.3 ± 0.6</td>
<td>2.5 ± 0.9</td>
<td>3.0 ± 0.5</td>
<td>2.8 ± 0.3</td>
<td>3.2 ± 1.0</td>
</tr>
</tbody>
</table>

Lung injury scores of non-LPS and LPS-exposed animals ventilated at positive inspiratory pressure (PIP) 26 cmH2O/positive end-expiratory pressure (PEEP) 5 cmH2O, with (Cap+) or without (Cap-) pretreatment with captopril. Nonventilated animals served as controls. Data are presented as mean ± SD. *p<0.05, compared with the non-LPS exposed animals with or without captopril.

### Figure 5

Hematoxylin and eosin staining of lung tissue of non-LPS exposed, nonventilated (A and E) and mechanically ventilated (MV) (positive inspiratory pressure (PIP) 26 cmH2O/positive end-expiratory pressure (PEEP) 5 cmH2O) animals (B and F). LPS-exposed nonventilated (C and G) and mechanically ventilated (PIP 26 cmH2O/PEEP 5 cmH2O) animals (D and H) without (A-D) or with (G-H) captopril pretreatment. Original magnification, ×20.
Figure 6. Immunohistochemistry for angiotensin-converting enzyme (ACE) in lung tissue of non-LPS exposed (A-C) or LPS-exposed (D-F) animals, which were either nonventilated (A and D) or mechanically ventilated (MV) (positive inspiratory pressure (PIP) 26 cmH\textsubscript{2}O/positive end-expiratory pressure (PEEP) 5 cmH\textsubscript{2}O) without (B and E) or with (C and F) captopril pretreatment. Diffuse staining was found on endothelial cells and also on cells in the alveolar walls. Original magnification, x 20.

Figure 7. Dual immunohistochemistry for angiotensin-converting enzyme (ACE) (developed by vector blue) and macrophage marker ED-1 (A and B) or epithelial cell marker AE1/AE3 (C and D; both developed by liquid permanent red) in lung tissue of non-LPS exposed (A and C) or LPS-exposed (B and D) animals which were ventilated with moderate pressure amplitudes (positive inspiratory pressure (PIP) 26 cmH\textsubscript{2}O/positive end-expiratory pressure (PEEP) 5 cmH\textsubscript{2}O). Co-staining showed ACE-positive alveolar macrophages (arrows and insets) and ACE-positive alveolar epithelial cells (arrowheads). Original magnification, x20; insets, x100.

not significant. Pretreatment with captopril had no effect on the surface area of AT1-staining in LPS-exposed animals that were, or were not, mechanically ventilated. Double staining of the lung tissue showed that the AT1-positive cells are alveolar macrophages and alveolar epithelial cells (Figure 9, A and B).
Discussion

In the present study, ventilation of preinjured (ie, LPS-exposed) lungs resulted in an exaggerated inflammatory mediator production via ACE-induced Ang II. The P/V loops, reflecting respiratory compliance and elastic properties, were attenuated in ventilated LPS-exposed lungs via ACE. This indicates that ACE mediates acute injury in LPS-exposed lungs. However, this was not corroborated by histological data. Overall, these findings support the concept that modulation of the RAS may intervene with VILI in patients with ALI/ARDS, with or without pre-existing lung injury.

Ventilation of healthy animals results in an inflammatory response in the lung that is mediated by ACE via an increased production of its effector-peptide, Ang II (Wösten-van Asperen et al., 2008; Jerng et al., 2007). In the present study, ventilated LPS-exposed animals had markedly enhanced BALF Ang II levels and enhanced expression in the lungs of the Ang II receptor, AT1. BALF protein levels and inflammatory mediator production were reduced by the Ang II antagonist, losartan, to a larger extent than after blocking ACE. Taken together, these results are highly suggestive of Ang II also being an intermediary in VILI of LPS-exposed lungs. In other models of ALI (ie, acid and
ACE in MV of LPS-exposed rats

sepsis-induced lung injury), it was shown that lung injury was also regulated by ACE via Ang II (Imai et al., 2005). Both ACE and AT1 receptor knockout mice showed reduced symptoms of ALI; it was concluded that ACE, via Ang II and its AT1 receptor, functions as a lung injury-promoting factor (Imai et al., 2005). It is unclear whether BALF ACE is derived from the airways and/or from the circulation. The localization of AT1 receptor on the alveolar epithelial cells and on macrophages suggests the presence of a local (pulmonary) RAS. This is strengthened by the fact that these cells are capable of producing RAS components in vitro (Wang et al., 1999; Uhal et al., 2007) and by our immunohistochemistry data that show that alveolar macrophages and alveolar epithelial cells contain ACE. However, it can not be excluded that ACE in alveolar macrophages is acquired by uptake. Moreover, we did not find an increase in pulmonary ACE and AT1 receptor staining in the various experimental groups. This suggests that enhanced leakage of systemic ACE, rather than enhanced local ACE and AT1 protein levels, affect the regulation of the RAS system in the lung under these conditions. In situ hybridizations may provide final proof for a role of a local RAS.

Whereas blocking of ACE inhibited the amount of proinflammatory mediators and improved lung mechanics, no effect on lung injury scores was found. We have two explanations for the absence of an improved histopathology. Firstly, a relatively high amount of LPS was used that caused substantial lung injury by itself. This injury was not accompanied by an increase in BALF ACE activity. In fact, the effect of LPS may have overshadowed a possible effect of ACE inhibition. Secondly, samples for immunohistopathology were collected after 4 hours of mechanical ventilation only. Likely, the attenuated proinflammatory mediator production by ACE inhibition may result in a reduced lung injury at later time points. This explanation is supported by the studies of Wang et al. (2009) and Hagiwara et al. (2009), who showed reduced lung injury scores 12 to 24 hours after the initial insult of the lung of rodents.

Differences in systemic blood pressure and the use of hyperoxia can potentiate lung injury during ventilation (Quinn et al., 2002). In the present study, however, they are not expected to be confounding factors. Previous studies showed that hyperoxia did not affect BALF ACE activity, protein content, or levels of inflammatory parameters (Wösten-van Asperen et al., 2008; Sinclair et al., 2004; Bailey et al., 2008). It is also unlikely that the observed decrease of blood pressure after captopril pretreatment and/or LPS during ventilation accounts for the differences in inflammatory response. It was shown that a decrease in LPS-induced pulmonary neutrophil recruitment after ACE inhibition was not paralleled by changes in blood pressure. Furthermore, pretreatment with another antihypertensive agent (without affecting ACE activity) had no effect on neutrophil accumulation despite a similar effect on blood pressure as compared with the ACE inhibitor (Arndt et al., 2006). It was also reported that correction of hypotension during high tidal volume ventilation did not change microvascular leak in the lung (Guery et al., 2003). In
contrast, antitumor necrosis factor antibodies prevented lung permeability (Choi et al., 2003). Taken together, these data suggest that inflammatory, rather than hemodynamic, mechanisms are involved in VILI. Indeed, the present study has shown that pretreatment with captopril is associated with an attenuated inflammation despite lower blood pressure. Differences in arterial pH and PaCO₂ may also be potential confounding factors because of the known injurious effect of hypocapnic alkalosis on ventilator-associated lung injury (Laffey et al., 2000; Laffey et al., 2003). In the present study, however, no differences were found in pH and PCO₂ values between the experimental groups during mechanical ventilation. Therefore, the differences in inflammatory response in these groups cannot be attributed to high pH or to low PCO₂ values.

The main conclusion of this study is that the exaggerated lung inflammatory response in ventilated LPS-exposed rats is driven by ACE via its key effector peptide Ang II. This finding may have important clinical implications. Therapeutic agents that block the production of Ang II (ACE inhibitors) or the effect of Ang II (Ang II receptor antagonists) might be used to prevent ventilator-induced injury imposed on a preinjured lung. These drugs would dampen the mediator response and improve dynamic lung function, thereby improving the prognosis of ALI/ARDS. It would be interesting to assess whether the application of captopril after mechanical ventilation and LPS exposure is just as effective as before the insults.